Table 2.

Weight Change According to DTG-Containing Regimen

Weight	3TC + DTG		RPV + DTG		PI + DTG		3TC/ABC/DTG		TDF/FTC + DTG		TAF/FTC + DTG
	No.	Mean	No.	Mean	No.	Mean	No.	Mean	No.	Mean	No.	Mean
T1-T0	75	–0.1 ± 0.4	45	0.8 ± 0.3a	60	1.2 ± 0.3a	326	0.1 ± 0.2	148	1.5 ± 0.3a	59	1.3 ± 0.5a
T2-T1	44	1.0 ± 0.4a	34	0.6 ± 0.6	51	0.1 ± 0.3	250	0.1 ± 0.2	137	1.0 ± 0.4a	14	1.6 ± 0.4a
T3-T2	28	–0.7 ± 0.2a	30	0.4 ± 0.3	40	–0.2 ± 0.3	191	–0.3 ± 0.2	115	0.3 ± 0.5	3	–1.0 ± 0.6
T4-T3	24	–0.3 ± 1.0	27	–0.2 ± 0.4	36	0.3 ± 0.5	150	0.5 ± 0.3	92	0.5 ± 0.3	1	–

T0 = baseline; T1 = 6 months; T2 = 12 months; T3 = 18 months; T4 = 24 months.

Abbreviations: 3TC, lamivudine; ABC, abacavir; DTG, dolutegravir; FTC, emtricitabine; RPV, rilpivirine; PI, protease inhibitor (atazanavir, darunavir); TAF, tenofovir alafenamide; TDF, tenofovir disoproxil fumarate.

^a P < .05 for change from baseline (T1-T0) or previous follow-up visit (T2-T1, T3-T2, T4-T3).